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Abstract
 Background & Aims—Chronic inflammatory bowel diseases (IBDs) have been associated 
with an abnormal mucosal response to the gastrointestinal microbiota. Although dietary fiber 
affects the gastrointestinal microbiota, there is limited information on the role of fiber on IBD 
activity. We investigated factors associated with fiber consumption and whether it was associated 
with flares in patients with IBD.
 Methods—We collected a completed 26-item dietary survey from 1619 participants in the 
Crohn’s and Colitis Foundation of America Partners Internet cohort (Crohn’s disease, 1130; 
ulcerative colitis/indeterminate colitis, 489). Eligible individuals were in remission based on 
disease activity index at baseline and completed a follow-up survey 6 months later. Fiber and 
whole grain consumption were categorized into quartiles and deciles. Disease flare at 6 months 
was defined as a disease activity index score exceeding remission cut-off values, and/or an IBD-
related surgical procedure or hospitalization since baseline.
 Results—Participants with longer duration of disease, past history of surgery and past IBD 
hospitalization ate less fiber. The risks for disease flare differed by disease type. Compared to 
those in the lowest quartile of fiber consumption, participants with Crohn’s disease in the highest 
quartile were less likely to have a flare (adjusted odds ratios [OR], 0.58, 95% confidence interval 
[CI], 0.37–0.90). Participants with Crohn’s disease who reported that they did not avoid high fiber 
foods were ~40% less likely to have a disease flare than those who avoided high fiber foods 
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(adjusted OR, 0.59; 95% CI, 0.43–0.81). There was no association between fiber intake and flares 
in patients with ulcerative colitis (adjusted OR, 1.82; 95% CI, 0.92–3.60).
 Conclusions—Intake of dietary fiber is associated with reduced disease flares in patients with 
Crohn’s disease, but not UC. Recommendations to limit dietary fiber should be reevaluated.
Keywords
inflammatory bowel disease; diet; microbiota; dysbiosis; short-chain fatty acids; food; CD; UC
 BACKGROUND
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases 
(IBDs) that can have a significant impact on quality of life. IBD is thought to result from an 
abnormal mucosal immune response to commensal gut bacteria in genetically susceptible 
individuals. Diet, particularly dietary fiber, can influence the gastrointestinal microbiota and 
potentially impact IBD course.
Information on the role of dietary fiber in the treatment and maintenance of IBD is limited 
despite more than 3 decades of study. A systematic review identified 23 randomized 
controlled trials that provided weak evidence of benefit.1 The studies were typically small 
and of short duration. Although there are reasons to think that fiber could have a beneficial 
influence through generation of short chain fatty acids such as butyrate, patients with IBD 
are often instructed to limit their fiber consumption.
We took advantage of dietary information provided by a large number of IBD participants 
enrolled in an Internet-based cohort study to explore the effect of self-reported dietary fiber 
consumption on disease activity. We sought to describe demographic and disease related 
factors associated with baseline fiber consumption and determine whether fiber consumption 
would predict disease flare at 6 months.
 METHODS
Data were derived from the Crohn’s and Colitis Foundation of America (CCFA) Partners 
Study. CCFA Partners is a longitudinal Internet-based cohort of more than 14,000 
participants with IBD. The development of the cohort has been described in detail 
previously.2 Briefly, individuals with IBD who were older than 18 years of age were 
recruited to join CCFA Partners using CCFA email rosters, social media, educational and 
fundraising events and the CCFA Website. Each participant completed a baseline survey that 
contained questions about demographic characteristics, treatments, disease duration, and 
disease activity. Follow-up surveys have been completed every six months to capture 
changes in disease activity and treatment since the prior survey. A randomly selected subset 
of participants completed an optional survey module about diet at initial enrollment. The 
study population for the current analysis is comprised of members of the CCFA Partners 
cohort who completed the baseline dietary survey module, were in remission at baseline, and 
subsequently completed a six-month follow-up survey.
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The dietary survey used for this study was a 26-item validated Dietary Screener 
Questionnaire (DSQ) that was developed by the Risk Factor Monitoring and Methods 
Branch of the National Cancer Institute (NCI).3–5 The survey asks about the frequency of 
consumption in the past month of selected foods and drinks. Comparing the screener to 
multiple 24-hour recalls, correlation coefficients for fiber intake range from 0.54 to 0.55 for 
women and from 0.52 to 0.60 for men.5 For the current analyses we used algorithms 
developed by the NCI for use with the DSQ to calculate consumption of whole grains and 
fiber. Fiber and whole grain consumption were categorized into quartiles and deciles.
Disease activity was classified using the Short Crohn’s Disease Activity Index (sCDAI)6 and 
the Simple Clinical Colitis Activity Index (SCCAI).7 Remission was defined as sCDAI score 
<150 or a SCCAI ≤2. Disease flare at 6 months was defined as a disease activity index score 
exceeding the cut-off for remission, and/or the need for an IBD-related surgical procedure or 
IBD-related hospitalization during the 6-month follow-up period. Pre-baseline history of 
IBD surgery and hospitalization were dichotomous variables. Indeterminate colitis was 
grouped with ulcerative colitis for these analyses.
All statistical analyses were performed using SAS version 9.3 (Cary, NC). Categorical 
variables were expressed as proportions and compared using chi square tests. Logistic 
regression models were used to predict disease flare at 6 months. We assessed possible effect 
modification by disease type (CD versus UC/IC). Potential confounders were selected using 
change-in-estimate methods and a priori knowledge. The study was approved by the 
Institutional Review Board of the University of North Carolina, Chapel Hill.
 RESULTS
A total of 1619 adults in remission at baseline completed a diet survey and a 6-month 
follow-up survey (Crohn’s disease, 1130; ulcerative colitis/indeterminate colitis, 489). 
Demographic and descriptive characteristics of the study population are shown in Table 1. 
Participant ages were distributed throughout all adult decades of life. Half (50.1%) of 
participants reported a disease duration of 11 years or greater.
We compared the characteristics of participants in the top versus bottom quartiles of fiber 
consumption [Table 2]. UC and male gender were strongly associated with higher fiber 
consumption, specifically participants with UC were 2.6 times more likely to be in the 
highest quartile of fiber consumption when compared to participants with CD, OR 2.63 
(95% CI 1.91–3.62). Men were almost 5 times more likely than women to be high fiber 
consumers, OR 4.74 (95% CI 3.34–6.73). Overall, there was no difference in fiber 
consumption by age, weight, or flare at 6 months, with flare at follow- up based on disease 
activity index alone, or with a broader definition of flare that included hospitalization or IBD 
surgery between baseline and follow-up surveys. Participants with longer duration of 
disease, past history of surgery or past hospitalization for IBD ate less fiber. Current IBD 
medication use was not related to fiber consumption.
Disease flare was defined as participants who were no longer in remission based on disease 
activity index at follow-up, or who required IBD-related hospitalization or surgery between 
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baseline and follow-up. Table 3 shows ORs for flare at 6 months, stratified by disease type. 
Among CD participants, those in the highest quartile of fiber were significantly less likely to 
have a flare, crude OR 0.57 (95% CI 0.38–0.86). After adjusting for sex, age, previous 
history of surgery or hospitalization, duration of disease and body weight, results were 
similar, adjusted OR 0.58 (95% CI 0.37–0.90). We compared each quartile to the lowest 
quartile to be certain that the fourth quartile results were not anomalous. For CD the point 
estimates for quartiles 2 and 3 were intermediate between the reference and quartile 4. For 
UC the trends were less clear but were generally consistent with the data presented in Table 
3.
To see if a more extreme value of high fiber might be protective, we compared the top 10% 
(decile) to the lowest decile. The effect size was more pronounced than the quartile analysis, 
adjusted OR 0.37 (95% CI 0.16–0.85). Results were similar for whole grain consumption, 
with highest quartile whole grain consumers significantly less likely to flare, crude OR 0.62 
(95% CI 0.41–0.94), adjusted OR 0.66 (95% CI 0.43–1.01) To be certain that patients 
categorized as in remission at baseline did not have a flare shortly prior to enrollment or 
were not maintained in remission by steroids, we conducted a sensitivity analysis that 
excluded any patient on steroids at baseline or who had an IBD hospitalization during the 12 
months prior to baseline. The results were unchanged.
In contrast, among UC/IC patients, effect estimates suggested that high fiber consumption 
was not associated with the likelihood of flare, with crude and adjusted ORs for quartile 4-
versus-1 of 1.38 ( 95% CI 0.74–2.60) and 1.82 (95% CI 0.92–3.60) respectively. The effect 
was greater when comparing the highest and lowest deciles, adjusted OR 4.78 (95% CI 
1.05–21.66). Whole grain consumption among UC patients had a similar relationship, with 
adjusted ORs for flare of 1.25 (95% CI 0.68–2.31) for the quartile-based analysis, and an 
imprecise but significant OR 3.29 (95% CI1.02–10.59) for decile-based analysis.
The Diet Screener Questionnaire used for this analysis asked participants to indicate the 
specific brand of cereals consumed, from a list of over 300 brands. We identified the seven 
cereals with the highest fiber content (“ultra-high fiber bran cereals”). Only 10 persons 
(0.62%) reported using any of the 7 ultra-high fiber bran cereals; 7 of these 10 were in the 
top quartile of fiber intake, and 5 of 10 were in the top decile. The proportion of ultra-high 
fiber bran cereal users was similar in CD versus UC participants. Our survey also included 
questions about avoidance of certain types of foods, including “high fiber foods”. There 
were 479 (29.6%) participants who said they avoided high fiber foods; none of these were 
ultra-high fiber bran cereal users. Compared to fiber avoiders, the small number (10) of 
ultra-high fiber bran cereal users were less than half as likely to flare, adjusted OR 0.42 
(95% CI 0.05–3.72). Additionally, CD participants who reported that they did not avoid 
high-fiber foods were about 40% lower likelihood of flare than those who avoided high fiber 
foods, adjusted OR 0.59 (95% CI 0.43–0.81).
We assessed possible effect modification of the association between fiber intake and flare 
across strata of each covariate: IBD subtype, sex, history of IBD hospitalization and surgery, 
duration of disease and age. We found an effect modification by disease subtype (CD, UC/
IC), and therefore reported all results stratified by IBD subtype. We did not observe effect 
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modification, qualitatively or statistically, for age, sex, history of IBD hospitalization and 
surgery, or duration of disease, thus did not report stratum-specific effects for these 
variables.
 DISCUSSION
The present study found striking differences in fiber consumption by disease type – UC 
participants consumed more fiber than did participants with CD. Female gender, prior 
hospitalization and prior surgery were all associated with lower fiber intake. The relationship 
between fiber consumption and flare at follow-up differed between CD and UC participants; 
the highest quartile fiber consumption was associated with a 40% lower odds of disease flare 
at 6 months among CD participants, whereas fiber intake amongst UC participants had no 
significant association with disease flare at 6 months. Some adjusted estimates for ulcerative 
colitis suggested that fiber increased the risk of flare. Because these were based on small 
numbers, the confidence intervals are very wide and the point estimates unstable.
The fiber intake in our population is similar to that of the US population. NHANES 2009–
2010 reports fiber intake as approximately 17 g/day among adults. A 2012 publication 
reports mean fiber intake for adults as 15.9 g/day for 2008.8 In our study population intake is 
comparable, with overall mean fiber intake of 16.1 and 18.0 g/day for CD and UC, 
respectively. The means in the highest quartiles was considerably higher, with means of 23.7 
(CD) and 24.5 (UC).
Since at least the 1970s, researchers have hypothesized that the lack of dietary fiber in 
industrialized diets is an important factor in the emergence of IBD.9 Recent technological 
advancements, such as culture-independent characterization of microbes, have increased the 
scientific understanding of gut microbiota10 and shown the relevance of dysbiosis to IBD.11 
Scientists worldwide are testing the therapeutic use of dietary fiber to improve gut function 
in IBD by affecting microbial balance and increasing fiber metabolites (short-chain fatty 
acids).12–23 Whereas most prior research focused on fiber supplements, the Partners data 
supports the idea that the fiber content of everyday foods may be an important variable in 
IBD disease course.
In 1979, Heaton et al. analyzed outcomes of 32 patients with CD who were treated for a 
mean of 4 years with a fiber-rich, unrefined carbohydrate diet in addition to conventional 
management, comparing outcomes with those of 32 matched patients with CD who received 
no dietary instruction. Similar to our findings in CD, Heaton et al. found that the higher fiber 
group had fewer hospitalizations than the group receiving no diet instruction (11 
hospitalizations and 34 hospitalizations, respectively; P < 0.01). The high fiber group had 
fewer surgeries and spent fewer days in the hospital than the group that received no dietary 
instruction, even excluding hospitalizations due to surgeries (80 days in the high fiber group; 
414 days in the group with no diet instruction; P < 0.01). Incidentally, Heaton et al. (1979)24 
reported that in all of their combined 150 patient years of recommending a fiber-rich diet for 
CD, no patient developed obstructions, despite the fact that many of their patients had a 
previous history of strictures before starting a fiber-rich pattern of eating.
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It is not clear whether the lower fiber consumption in CD participants in the present study is 
the result of physician instructions or participant preference. Participants with stricturing 
disease may avoid fiber because they encounter symptoms, particularly bloating, when they 
eat certain fibrous foods. It is possible that patients with strictures might avoid fiber to 
prevent obstructive symptoms. If they flared in the next 6 months we would erroneously 
attribute the flare to fiber avoidance. Because we did not have accurate information on 
disease phenotype we cannot exclude that possibility. Conversely, it may be that post-
surgical participants continued with a low fiber diet after it was warranted, because they 
received little post-operative nutritional counseling.
Few participants in this sample consumed ultra-high fiber bran cereal. Although consumer 
demand has kept All Bran® cereals on U.S. grocery store shelves since 1916,25 only 25 out 
of 3,274 (<1%) Partners participants who answered the questions about cereal brands 
reported consuming All Bran® or any similar cereals. Also, we have documented in this 
large sample that 30% of participants avoid dietary fiber altogether. It is unknown how much 
of this fiber restriction is caused by medical necessity and how much is caused by 
incomplete and imbalanced fiber information favoring reduction of fiber for individuals with 
IBD.
We observed that the risk of flare at 6 months differed by IBD type. This differential effect is 
not unexpected, and in fact, the effect of many environmental exposures on IBD outcomes 
are different for CD and UC. Smoking is perhaps the most-studied example. Smoking is a 
clear risk factor for CD relapse and post-operative recurrence; however, it may have a 
protective effect for patients with UC.26
Among CD participants, the higher rate of flares at 6 months for fiber avoiders versus non-
avoiders suggests a need for further research. Important questions remain regarding the 
underlying cause of dietary fiber restriction as well as the effect of dietary fiber in 
individuals with gut pathophysiology characteristic of IBD. First, it is unknown if the 
association between fiber restriction and increased disease activity represents a causal 
relationship. Second, if there is a causal relationship, it is unknown which came first. 
Participants in the study who avoid fiber may have been destined to have problems due to 
more aggressive disease phenotypes with significant stricturing that causes them to avoid 
fiber. In contrast, plausible mechanisms published in support of fiber for CD research27 
could explain the significantly lower disease activity found in the group that did not avoid 
fiber.
Our study has limitations. The dietary information was obtained by a short validated 
screener.4, 5 It is possible that the fiber intake was measured inaccurately. We believe that 
any misclassification of fiber intake was random which would bias the study toward the null. 
Despite the large size of the study, the numbers of participants in certain subgroups was 
limited. We do not have accurate information from this Internet survey about disease 
phenotype, particularly stricturing disease in CD. However, in sensitivity analyses among 
CD patients, effect estimates were very similar after excluding those with any history of IBD 
surgery or hospitalization, suggesting that our observations of protective effects of fiber 
intake on flare was not influenced by aggressive phenotypes. The survey was not designed to 
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test the fiber hypothesis, and for that reason there were not detailed questions about specific 
fiber types. We defined ‘flare’ as participants with an elevated disease activity index, 
hospitalization or surgery at the 6-month follow-up. It is possible that participants were 
beginning to flare at baseline and changed their diet as a consequence. There were only a 
small number of participants who ate ultra-high fiber bran cereals, therefore limiting these 
subgroup analyses. Although this study is strengthened by its prospective design over a 6 
month follow-up, compared to the progression of IBD disease activity over many years, the 
follow-up period of this study is limited.
The results of this study support findings reported in investigations occurring in the 1980s – 
low fiber eating does not result in improved outcomes for individuals with CD compared to 
individuals with CD not restricting fiber intake.28, 29 More research is needed to explore the 
causes of fiber restriction in CD. More prospective studies are needed to explore the 
potential benefits of fiber-containing foods in the diet of individuals with IBD, especially in 
specific phenotypes. As suggested by the authors of a recent IBD diet review,30 it is unlikely 
that a single diet will be found to be sufficient to manage all IBD phenotypes; however, it 
will be remarkable progress if a diet is found to be sufficient alone for some and adjunctive 
therapy for others.
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Table 1
Characteristics of the study population
N = 1619 Stratum Crohns n = 1130 Ulcerative colitis n = 489
Sex, n (%) Male 338 (29.9) 151 (30.9)
female 792 (70.1) 338 (69.1)
Age category, n (%) <=30 246 (21.8) 112 (22.9)
31–40 241 (21.3) 98 (20.0)
41–50 202 (17.9) 105 (21.5)
51–60 252 (22.3) 87 (17.8)
>60 189 (16.7) 87 (17.8)
Duration of disease, n (%) 0–1 yr 81 (7.2) 40 (8.2)
02–5 yrs 227 (20.1) 114 (23.4)
06–10 yrs 223 (19.8) 122 (25.0)
11–20 yrs 280 (24.8) 120 (24.6)
>20 yrs 316 (28.0) 92 (18.9)
History of surgery, n (%) No 615 (54.4) 472 (96.5)
Yes 515 (45.6) 17 (3.5)
History of hospitalization, n (%) No 349 (30.9) 306 (62.6)
Yes 781 (69.1) 183 (37.4)
Fiber intake, g/day
 Mean (std) 16.0 (6.5) 18.0 (7.4)
 Median (IQR) 14.6 (11.6–18.6) 16.1 (13.3–21.1)
Whole grain intake, oz eq/day
 Mean (std) 1.0 (1.4) 1.3 (1.6)
 Median (IQR) 0.6 (0.2–1.2) 0.8 (0.3–1.6)
Flare at follow-up
 Total flare (sCDAI/SCAI or hospitalized/surgery) No 877 (77.6) 354 (72.4)
Yes 253 (22.4) 135 (27.6)
 Defined by sCDAI/SCAI No 927 (82.0) 365 (74.6)
Yes 203 (18.0) 124 (25.4)
 # hospitalized or surgery No 1080 (95.6) 478 (97.8)
Yes 50 (4.4) 11 (2.2)
Median (IQR) baseline disease activity scores, sCDAI (Crohns) or 
SCAI (UC)
79 (58,107) 1 (1,2)
Quartile of body weight Q1: 85–130 lbs 283 (25.1) 138 (28.2)
Q2: 131–152 lbs 276 (24.4) 118 (24.1)
Q3: 153–180 lbs 303 (26.8) 119 (24.3)
Q4: 180.4–353 lbs 267 (23.6) 114 (23.3)
Current use of steroids No 1065 (94.2) 464 (94.9)
Yes 65 (5.8) 25 (5.1)
Current use of immunosuppressants No 200 (35.0) 66 (35.7)
Yes 372 (65.0) 119 (64.3)
Current use of aminosalicylates No 200 (30.8) 66 (15.4)
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N = 1619 Stratum Crohns n = 1130 Ulcerative colitis n = 489
Yes 450 (69.2) 363 (84.6)
Current use of biologics No 200 (32.0) 66 (44.6)
Yes 425 (68.0) 82 (55.4)
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